BoB@JPM: Rick Modi, Affinia Therapeutics

Business Of Biotech

We love to hear from our listeners. Send us a message.

The latest in our series of Business of Biotech podcasts recorded in-person at JPM in San Francisco features an inspiring conversation with Affinia Therapeutics CEO Rick Modi. Modi shares on how his upbringing in Kenya shaped his adversity-embracing worldview, and how that worldview contributes to his biotech leadership. We cover his transition from pharmaceutical work in Iowa to a career in biotech, the gene therapy advances Affinia is building on, the company's investment approach, its upcoming clinical trials, and much more.
The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Chapters

1. Introduction to Rick Mody (00:00:00)

2. The Journey from Kenya to Pharmacy School (00:01:50)

3. Adapting to Life in the U.S. (00:15:30)

4. Transitioning from Pharmacy to Pharma (00:22:20)

5. The Start of an Entrepreneurial Journey (00:35:00)

6. The Science Behind Affinia Therapeutics (00:49:15)

7. Innovations in Gene Therapy (01:05:00)

8. Financial Insights and Investor Perspectives (01:15:50)

9. Future Directions for Affinia (01:30:10)